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Abstract
The fact that in vivo the extracellular matrix or substratum with which cells interact often includes
topography at the nanoscale underscores the importance of investigating cell-substrate interactions
and performing cell culture at the submicron scale. An important and exciting direction of research
in nanomedicine would be to gain an understanding and exploit the cellular response to
nanostructures. Electrospinning is a simple and versatile technique that can produce a macroporous
scaffold comprising randomly oriented or aligned nanofibers. It can also accommodate the
incorporation of drug delivery function into the fibrous scaffold. Endowed with both topographical
and biochemical signals such electrospun nanofibrous scaffolds may provide an optimal
microenvironment for the seeded cells. This review covers the analysis and control of the
electrospinning process, and describes the types of electrospun fibers fabricated for biomedical
applications such as drug delivery and tissue engineering.
1. Introduction
Nanomedicine profits from the innovative application of nanotechnology to medicine. An area
of interest is to produce synthetic analogs of the extracellular matrix, which contains many
nanoscale features. Such biomimetic nanostructures would have important implications in the
basic studies of cell biology and in applications for regenerative medicine and medical device
design. The nanoscale comes into the picture because in vivo the extracellular matrix or
substratum with which cells interact often includes topography at the submicron scale. For
example, the basement membrane that separates tissues such as epithelia, endothelia, muscle
fibers, and the nervous system from connective tissue compartments possesses a complex
mixture of pores, ridges, and fibers with sizes in the nanometer range [1,2]. The literature
clearly indicates that cells respond to the nanotopography of synthetic substrates in terms of
adhesion, proliferation, migration, and gene expression. An important and exciting direction
of research in nanomedicine would be to gain a fundamental understanding of how cells
respond to nanostructures. This would be best accomplished by conducting cell culture studies
on well-defined nanostructures produced by techniques perfected for microelectronics
industry, such as electron beam lithography, x-ray lithography, laser ablation, nano-embossing,
and nanoimprinting. However, in parallel there is also a need to produce nanostructures by
simple fabrication techniques for applications such as tissue engineering.
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Tissue engineering takes many forms. Most approaches involve a scaffold for cells to attach,
differentiate, proliferate, and eventually develop into a tissue suitable for implantation.
Alternatively the cells, particularly xenogenic or transformed cells, are encapsulated in a
semipermeable membrane for immunoprotection and applied in vivo as part of a cell-based
artificial organ, or ex vivo as an extracorporeal device. Artificial pancreas and artificial liver
represent the latter examples. In all cases, a scaffold that can interact and influence the cellular
behavior is a crucial component.
Fibrous scaffolds are attractive for tissue engineering because of their inherent advantages of
high surface area for cell attachment, controlled porous architecture, and a 3-D
microenvironment for cell-cell contact. Conventional fibers produced by mechanical fiber
spinning usually measure tens of microns in diameter. Such fibers have relatively low specific
surface area and their diameters are far larger than the diameters usually encountered in nature.
Smaller, submicron-diameter polymeric fibers, or nanofibers, may provide stronger
topographic cues by mimicking the filamentary ECM. Nanofibers composed of natural or
biodegradable polymers can also be tailor-designed to possess the tissue-matching mechanical
compliance. Unlike carbon nanotubes or other metallic nanorods, continuous polymeric
nanofibers may also have reduced potential health hazards that are associated with
discontinuous nanomaterials and nanoparticles [3,4]. Another advantage of electrospinning is
the possibility of encapsulating drugs in the fibers. Optimal tissue engineering requires more
than an inert scaffold to serve merely as a substrate for cell attachment and cell growth. Cues
or signal molecules in the form of adhesion molecules, growth and differentiation factors, or
even plasmid DNA, should be incorporated into these scaffolds in a spatially defined manner
to orchestrate the growth of new tissue. Growth factors encapsulated in electrospun nanofibers
constitute a biofunctional scaffold that may best mimic the ECM.
Until recently, there are no techniques that can manufacture nanofibers economically.
Conventional mechanical fiber spinning cannot produce fibers with diameters smaller than 2
micrometers. Melt blowing produces non-woven mats of fibers with diameters around or
slightly below a micrometer. However, these fibers tend to be discontinuous and highly non-
uniform in diameter. An island-in-the-sea method based on mechanical spinning of polymer
blends with subsequent removal of selected components produces fibers of micron or slightly
submicron diameters [5]. This method is however very expensive. One technique that can
consistently produce continuous polymeric nanofibers is electrospinning.
2. Electrospinning Process
2.1. Experimental Process Setup and Examples of Resulting Nanofibers
Electrospinning consists of spinning polymer solutions or melts in high electric fields. A
schematic of the process is shown in Fig. 1. The process is based on the principle that strong
electrical forces overcome weaker forces of surface tension in the charged polymer liquid. At
certain threshold voltage, a fine charged jet is ejected from the tip of a capillary tube.
Subsequently, the jet moves in the direction of the external electric field, elongates according
to external and internal electrical forces, and experiences instabilities [6]. The jet segments are
then deposited on a substrate in the form of random nonwoven mat of nanofibers. Over 200
synthetic and natural polymers have been processed into nanofibers with diameters ranging
from 3 nanometers to several microns [6].
Electrospinning is an inexpensive process that can be easily scaled up, employing multiple
spinnerets. It is surprisingly versatile in that almost any soluble polymer can be processed into
nanofibers. Both conductive and dielectric polymer solutions have been successfully utilized.
Melts can also be spun into fibers but usually result in larger fiber diameters [7]. Composite
and hollow nanofibers, including nanofibers containing liquids have been produced by coaxial
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electrospinning [8-10]. Continuous carbon and ceramic nanofibers have also been produced
by modified processes [8,10-12]. Examples of several nanofibers that show promises for
biomedical applications are shown in Fig. 2. A list of biocompatible polymers that have been
electrospun shall be highlighted in the next section.
2.2. Fundamental Mechanisms of Jet Motion in Electrospinning
Electrospinning differs from conventional mechanical spinning used to produce synthetic
fibers in the way the driving force is applied to the jet. In conventional spinning, mechanical
force is applied at the end of the jet through a rotating mandrel. In electrospinning, volumetric
electrical forces are applied to charged jet particles. Creation of liquid jets by an electrostatic
field is a well-known phenomenon [13,14]. Such jets have been used in industrial processes,
e.g. electrostatic atomization and ink-jet printing. However, electrospinning differs
qualitatively from these electrically driven processes involving low-molecular weight liquids.
In the latter processes, the initially continuous jets break-up into droplets at a short distance
from the jet starting point [13,14]. The break-up is caused by varicose or Raleigh instability.
This instability is persistent and is the reason most liquids can be “atomized” into micron-sized
droplets through jet creation. It is also the reason, why relatively little effort has been devoted
over the years to study jet diameter variation in these processes at a substantial distance from
jet origination.
Electrospinning involves high molecular weight polymer liquids. Polymer chain entanglement
results in complex, non-linear rheological behaviour that complicates the analysis. This
complex rheology coupled with the strength of extended polymer chains (chemical versus
intermolecular bonds) suppress varicose instability and prevent jet break-up into droplets.
Assisted by unusual jet instability, long drawing distances result in fine jets that ultimately
solidify into nanofibers.
Modelling is essential for better understanding of this complex coupled process. For modelling
purpose, the process can be broken into several essential subprocesses, i.e. jet initiation, steady-
state spinning, and jet instabilities.
Jet initiation in electrospinning has been treated as a break-up of highly charged liquid meniscus
[15]. Such meniscus deforms in the electric field until beyond a certain threshold field a fine
jet is ejected from the meniscus. Usual energy-based analysis methods are not applicable to
this problem due to the variable volume and charge of the meniscus. A new approach based
on the asymptotic electromechanical analysis at the meniscus apex has been developed [15].
The general method can be used on dielectric and conductive polymer solutions. The resulting
stability diagrams can then be used to predict jet initiation [16].
Steady-state electrospinning is the continuous process of straight jet motion from the origin
towards the external electric field. The non-linear rheology of polymer fluids and the
volumetric nature of electric forces come into play. Several models of electrospun jets have
been developed recently [12,16]. Simple asymptotic exponents have been derived for various
jet flow regimes [17]. The above models provide insight into jet stretching in the initial stages
of the electrospinning process. Their results can be used as a starting point for jet instability
analysis.
One of the major breakthroughs that has substantially improved our understanding of the
electrospinning process is the discovery and explanation of “bending” or “whipping” instability
[18-20]. This instability transforms initially straight jet segments into “bent” jets that assume
spiral, helical, or serpentine shapes. The instability was discovered by analyzing high-speed
videos of the process. In the past, conventional photographs of the process appeared to show
massive jet splaying that started at a certain point down the jet stream and resulted in multiple
Chew et al. Page 3
Curr Pharm Des. Author manuscript; available in PMC 2008 May 25.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
smaller jets deposited on substrates. The evidence seems so compelling that even now many
publications continue to show splayed jets in their schematics. In reality, as seen on high-speed
video frames, the apparent splayed jets are nothing but traces of multiple bent jet segments
rapidly moving radially from the point of first bending instability [18]. The mechanism of this
instability is driven by the transverse components of the internal electrical forces in the
perturbed jet segments. Models of bending or whipping instabilities provide better insight into
the process and lead to better process control. Splaying instability, though more rare, has also
been observed in experiments and models. It is currently believed that jets instabilities may
occur hierarchically at the decreasing scales in the electrospinning process. The instabilities
intensify jet thinning and are therefore essential for production of ultrafine nanofibers.
In summary, electrospinning is a highly coupled process involving high-speed nonlinear
electrohydrodynamics, complex rheology, and transport of charge, mass, and heat within the
jet [6,21]. The process is characterized by massive jet instabilities that are persistent, occurring
at multiple scales, and responsible for jet thinning. Despite recent advances on process analysis
and modelling, much remains to be done. More sophisticated coupled models will provide
deeper insights into the mechanisms of jet thinning and instabilities and will further facilitate
process optimization.
2.3. Control of Nanofiber Diameter and Morphology
A major readout of the electrospinning process is the diameter of the fiber. So far, this is
controlled mostly empirically [22-24], relying on variation of polymer concentration and
molecular weight of the polymer. These parameters have great effect on polymer solution
viscosity that results in different jet thinning. For most polymer systems, variation of these two
parameters may produce nanofibers with diameters in the range of 50-1000 nm. The same
parameters also largely determine the spinnability of the polymer solutions. Solutions with low
polymer concentrations result in micronsize droplets (or particles, after solidification), as a
result of varicose jet instability, similar to low-molecular weight liquids. The threshold
concentration depends on the polymer molecular weight, the higher of which requires a lower
concentration. Intermediate concentration and molecular weight values often result in beaded
nanofibers (Fig. 3). It is likely that beading is initiated as varicose instability [25]. The fine
polymer threads between the beads are among the smallest polymer nanofibers produced by
electrospinning. For example, a fiber as small as 3 nm in diameter was observed [25].
Other fluid properties affecting jet flow in electrospinning are surface tension and dielectric
and electrical properties. Variation of these parameters, for instance, by addition of surfactants
or salts, can affect nanofiber diameter and morphology. For example, addition of salt and
surfactant can result in the suppression of beading in the system with otherwise similar
characteristics. Many other factors such as quality of solvent, diffusion coefficient, flow rate,
and parameters affecting solvent evaporation play an important role in electrospinning and
result in variation of nanofiber diameter and morphology. Temperature and other
environmental conditions are also critical.
Cross-sectional shape of electrospun nanofibers is usually circular. However, ribbon-like fibers
have also been produced [26]. An example of fine collagen ribbons produced by
electrospinning in our laboratories (YD) is shown in Fig. 4. Ribbon morphology is most likely
due to the collapse of rapidly solidified outer shell of electrospun jets. Another possible
mechanism is non-axisymmetric jet instability originating from a perturbation of jet cross-
sectional shape.
Nanofiber surface texture and porosity may be of critical importance for biomedical
applications. Nanoscale surface texture can provide additional topographical cues for cell
attachment and proliferation. Nanofiber porosity can affect specific fiber surface area that is
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important for sensing or drug delivery functions. It has been shown that nanofiber surface and
volumetric porosity and morphology can be controlled to a certain extent by the solvent type
[27-30]. For example, the use of volatile solvents has led to substantial nanofiber porosity as
shown in Fig. 5. Porous nanofibers as a result of phase separation in polymer-solvent systems
have also produced [27-29]. Electrospinning of co-polymers can lead to unusual surface texture
and properties [31]. Another technique that can produce nanofibers with surface or volumetric
texture is blend spinning, followed by removal of selected constituents [27,32].
2.4. Control of Nanofiber Orientation
Many biomedical applications would benefit from the ability to produce aligned nanofiber
assemblies. ECMs of a variety of tissues consist of aligned protein fibrils and bundles. Truthful
reproduction of such ECMs using electrospinning would require nanofiber alignment. Massive
hierarchical jet instabilities in electrospinning naturally result in random, nonwoven nanofiber
mats or sheets. Substantial effort has been devoted in the recent years to the development of
methods to achieve fiber alignment.
Conventional collection of nanofibers on the surface of a rotating drum or mandrel can produce
thick nanofibrous sheets [33], but typically results in only partial nanofiber alignment, even at
very high rotation velocities (Fig. 6). Nanofiber deposition onto the edge of a rotating disc
(essentially, a narrow mandrel) resulted in a band of nanofibers with relatively high alignment
[10]. However, it is difficult to use this method to produce high quality nanofiber sheets or 3D
assemblies desirable for tissue engineering. Several methods of alignment based on electrical
forces acting on charged jet segments have been explored recently [6,21]. One of the best
methods is to use split collecting electrodes (gap method – Fig. 7a) [21,34] to produce aligned
nanofibrous arrays or sheets (Fig. 7b). Sequential use of the method can result in highly
customized 3D nanofibrous constructs as illustrated in Fig. 7c.
2.5. Electrospun Biocompatible Materials
The versatility of the electrospinning process has allowed for many different polymers,
synthetic, natural or a blend of both, and even polysaccharides to be electrospun. Depending
on the type of processing parameters, particularly the types of solvent used, and the
concentration of polymer solution, fibers of different diameters can be obtained. There is
increasing interest in studying hybrid composite fibers composed of a blend of natural and
synthetic polymers. This is mainly due to the need to include both the superior mechanical
properties of synthetic polymers and the biocompatibility of natural polymers into one single
scaffold. Table 1 summarizes the various types of polymers and polysaccharide that has been
electrospun. These biocompatible materials may find useful applications as tissue scaffolds or
drug delivery vehicles.
In summary, nanofibers from biocompatible synthetic and natural polymers possess critical
advantages for surface modification of implants and design of tissue engineering scaffolds. In
contrast to patterned silicone or PDMS substrates, electrospun continuous nanofibers present
a unique route for the development of practical in vivo applications. The process is versatile
and provides a reasonable degree of control over the resulting size and morphology of the
nanofibers. At the same time, continuous nanofibers can possess good mechanical properties
to provide structural integrity for their assembly. Finally, in contrast to classical discontinuous
nanomaterials such as carbon nanotubes and various nanorods, continuous electrospun
nanofibers enjoy a macroscopic dimension that leads to easy handling, placement, processing
into devices, and reduction of potential toxicity in in vivo applications.
Chew et al. Page 5
Curr Pharm Des. Author manuscript; available in PMC 2008 May 25.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
3. Drug-Encapsulated Electrospun Fibers
Drug encapsulation in electrospun fibers is still relatively unexplored. The electrospinning
process can be easily adapted to accommodate encapsulation of different bioactive agents.
With a large surface area-to-volume ratio to facilitate efficient mass transport, drug-
encapsulated fibrous scaffolds may offer efficient delivery to the seeded cells. In this section,
we will review recent studies on incorporating controlled release functions in the form of low
molecular weight drugs, plasmid DNA, proteins and glycosaminoglycan salts into electrospun
fibers.
3.1. Fabrication
Solid or liquid drugs can be directly incorporated into electrospun nanofibers by composite
electrospinning. Coaxial electrospinning can be used to encapsulate a drug-delivering solid or
liquid core into a structural shell. The shell can be designed to produce controlled release via
controlled diffusion properties, porosity, or biodegradability.
3.2. Types of Drugs
3.2.1. Low Molecular Weight Drugs—A variety of low molecular weight drugs has been
electrospun, including lipophilic drugs such as Ibuprofen [35], Cefazolin [36], Rifampin [37],
Paclitaxel [37] and Itraconazole [38]; and hydrophilic drugs such as Mefoxin [24,39] and
tetracycline hydrochloride [40]. To date, the majority of the studies have been carried out with
polyesters, particularly poly(lactic acid)s (PLA) because of their biocompatibility and FDA-
approved status. Poly(ε-caprolactone) is another popular polyester because of its ease of
processing. In general, a burst release is often observed when low molecular weight drugs are
encapsulated in electrospun fibers. As a result, different attempts have been made to control
the drug release kinetics. Such attempts include: conjugation of the drug to the polymer [35],
alteration of drug-polymer interaction [35,39,40], use of enzymatically degradable polymer
matrix [37], and alteration of mass transport to and from the scaffolds using an additional matrix
[38].
3.2.1.1. Lipophilic Drugs: Ibuprofen, an anti-inflammatory agent, was loaded at 5wt% into
electrospun poly (L-lactic-co-glycolic acid) (PLGA, LA:GA 75:25, Mw 8 × 104) and PLGA/
PEG-g-chitosan (70:30 ratio) meshes in the form of a drug-polymer mixture by Jiang, et al.
[35] for atrial fibrillation application. The drug was also conjugated to PEG-g-chitosan and
electrospun at a drug loading level of 4.4wt% with PLGA, forming a drug-polymer conjugate.
Drug release analysis carried out in 0.1M PBS at 37°C revealed a burst release of close to 50%
from plain PLGA drug-encapsulated fibers, followed by a quick release of drugs by simple
diffusion resulting in more than 85% drug release after 4 days of incubation. The rapid release
was mainly associated with the lack of interaction between the drug and PLGA matrix [35].
By blending the drug with PEG-g-chitosan, the burst release was reduced to 20% and a
sustained release was obtained for at least 16 days due to the ionic interaction between the
carboxyl groups of the drug and chitosan. By conjugating the drug directly onto PEG-g-
chitosan, a pseudo-linear drug release profile, with less than 40% drug release after 16 days of
incubation was obtained. This is an excellent example of how physical and chemical
interactions between the drug and the polymer matrix can be manipulated to overcome the
rapid release kinetics of electrospun fibers.
Cefazolin, a broad-spectrum antibiotic was electrospun with PLGA 50:50 at different loading
levels of 0%, 10% and 30% [36]. By observing the resulting fiber morphology, the authors
optimized the electrospinning parameters accordingly for drug encapsulation. The authors
observed that drug-loaded fibers possessed larger diameters than plain fibers, with drug-loaded
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fibers having an average diameter ranging between 450 and 500 nm. The drug release kinetics
of Cefazolin, however, was not evaluated.
Rifampin, a drug for tuberculosis treatment was encapsulated in PLLA electrospun fibers at
loading levels up to 50wt% [37]. Incubation of the fibers with 15 and 25wt% of rifampin in
0.05M Tris-HCl, with and without proteinase K, at 37°C revealed that in the absence of
proteinase K, no drug release was observed. Degradation of PLLA fibers by proteinase K
resulted in a constant drug release rate, indicating that drug release from PLLA fibers occurred
via polymer degradation instead of diffusion. This can be easily explained by the poor water
solubility of Rifampin. Electrospinning of the anti-cancer drug, Paclitaxel, was also carried
out. The drug release profile of Paclitaxel, however, was not reported [37].
Itraconazole, a broad-spectrum antifungal agent loaded in hydroxypropylmethylcellulose
(HPMC) at 20 and 40% w/w was electrospun [38]. The in vitro drug release kinetics was studied
in 0.1N HCl at 37°C, under a rotation of 100rpm using various forms of electrospun fibers,
namely, free fibrous mesh, manually folded mesh, mesh inserted into a hard gelatin capsule
size 0 and mesh enclosed in a metal spiral. The results indicated that drug release was negligibly
altered by the change in drug loading level and electrical potential applied during
electrospinning. An initial burst release, followed by a complete drug release within 500
minutes of incubation in HCl was observed. By obstructing the mass transport to and from the
fibrous mesh through the encapsulation of the mesh in either a gelatin capsule, or a metal spiral,
drug release was sustained for up to 1500 minutes. However, such an approach does not take
advantage of the structural features of a fibrous mesh.
3.2.1.2. Hydrophilic Drugs: Mefoxin (Cefoxitin sodium), a general antibiotic was loaded at
1wt% in poly(D-lactic acid) (PDLA) [24] and 1 and 5wt% in PLGA or a mixture of PLGA/
PEG-b-PLA diblock copolymer [39] by electrospinning. Release studies for the PDLA and
PLGA fibers were conducted in PBS at room temperature and in water at 37°C respectively.
Similar to the observations made by Jiang, et al. [35], both studies revealed an initial burst
release of drugs from the polyesters within the first 3 hours of incubation (more than 80% drug
release from PDLA; 40% drug release for 1wt% loading and 70% drug release for 5wt% loading
from plain PLGA fibers; and 50% drug release at 5wt% loading from PLGA-PEG co-
polymers). Drug encapsulated at a theoretical loading efficiency of over 90% in PDLA was
completely released within the first 48hr. The burst and rapid release of the drug was related
to the salt form of the drug and the lack of interaction between the drug and the polyesters,
such that most of the drug was located either on or near the surface of the fibers [24]. In the
presence of PEG, Mefoxin may be encapsulated within the hydrophilic block of PEG-b-PLA,
hence reflecting a more sustained release of the drug (about 27% of drug continuously released
over a week after initial burst). A test for the bioactivity of the drug was also carried out using
S. aureus bacteria. The encapsulated drug maintained its bioactivity after the electrospinning
process as demonstrated by its ability to inhibit the growth of the bacteria for up to 24 hours
[39].
Tetracycline hydrochloride was encapsulated at 5wt% in poly(ethylene-co-vinyl acetate)
(PEVA), PLA and a 50/50 blend of the two polymers via electrospinning, with the aim of
applying the fibers to the treatment of periodontal disease [40]. Drug release kinetics observed
from placing the drug-loaded fibrous meshes into tris buffer showed that, similar to the
observations made by Zong, et al. [24], an initial burst release was observed from the PLA
fibers. Thereafter, drug release was negligible over the next 50 hours, which was similar to the
observations made by Zeng, et al. [37], whereby drug release was not observed from PLA
fibers in the absence of proteinase K. The release kinetics was probably due to the release of
drugs on the surface of the PLA fibers, and the subsequent restricted diffusion of the drugs
from the partially crystalline PLA fibers. The drug release was further hindered by the slow
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hydrolytic degradation rate of PLA, which probably was negligible within the period of the
study. Electrospun PEVA and polymer blend, however, showed a more continuous release of
drug, with 65% and 50% of the drugs released within 120 hours, respectively. The drug release
profiles were also compared to that of Actisite® periodontal PEVA fiber that was loaded with
25wt% of tetracycline hydrochloride. After the initial burst release, the drug release rate of
electrospun PEVA and polymer blend was similar to that of Actisite. Drug release from these
fibers was via molecular diffusion of the dissolved drug, since no obvious porosity was seen
on the fibers after drug release. A comparison of the drug release rate was also made with
solvent cast film of PEVA, PLA and the polymer blend, revealing a much faster release rate
from the electrospun fibers due to the increased surface area provided by the fibers.
3.2.1.3. Antimicrobial Agents: Melaiye, et al. [41] utilized Tecophilic, a family of hydrophilic
polyether-based thermoplastic aliphatic polyurethanes, to encapsulate silver (I) –imidazole
cyclophane gemdiol complex at loading levels of 25wt% and 75wt% via electrospinning.
Although the actual release kinetics of the silver complex was not evaluated, the antimicrobial
activity of the fibrous mesh was found to sustain for over a week. Evaluation of the bactericidal
activity of the encapsulated silver by incubation with various species of prokaryotes
(Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus) with the fibrous mesh
overnight at 35°C revealed that the fibrous mesh enhanced the antimicrobial activity of the
silver(I)-heterocyclic carbene complex on micro-organisms. It was also found that a much
lower concentration of silver complex was required than silvadene, a widely used clinical drug,
to kill bacteria at a much faster rate [41].
3.2.2. Plasmid DNA—Only one study has been reported on the use of electrospun fibers for
gene delivery [42]. The authors encapsulated pCMVβ plasmid DNA by electrospinning in the
polymer blend of PLGA 75:25 and PLA-PEG block copolymer at various weight ratios. The
study of the DNA release kinetics was subsequently carried out in Tris-EDTA buffer at 37°C
over a period of 20 days. Close to 68-80% of the encapsulated DNA was released within the
first 5 days of incubation, with the release profile plateauing thereafter for the remaining 15
days. Analysis of the release kinetics at early time points revealed a burst release within the
first 15min of incubating the scaffolds, and a dramatic decrease in DNA release after the initial
2 hours of incubation. The burst release of the DNA was most likely related to the portion of
DNA located on the surface of the fibers [42]. The rate and extent of DNA release decreased
with an increasing amount of block copolymer PLA-PEG. Therefore, this study, along with
the observations made by other researchers [24,35,39,40], emphasizes the importance of drug-
polymer interactions or drug partitioning in controlling drug release rates. With the evaluation
of the structural integrity and bioactivity of the released DNA by gel electrophoresis and
transfection of MC3T3 cell, the authors also demonstrated that the released DNA maintained
at least partial bioactivity after electrospinning.
3.2.3. Proteins—The encapsulation of proteins via electrospinning may appear to be a
challenging task due to the fact that denaturation of these macromolecules often occurs easily,
especially upon being subjected to harsh processing conditions such as high electrical potential
and the exposure to organic solvents. Nonetheless, two studies have successfully demonstrated
the possibility of encapsulating and releasing bioactive proteins from electrospun fibrous
meshes.
Similar to most other drug encapsulation studies, whereby a homogeneous drug-polymer
solution is electrospun, Zeng, et al. [43] encapsulated bovine serum albumin (BSA) (0.01wt
%) and Luciferase in poly(vinyl alcohol) (PVA) by electrospinning a homogeneous mixture
of protein-polymer aqueous solution. Protein release kinetics was assessed by incubating
electrospun fibers in water at either 4, 20 or 37°C. PVA/BSA fibers were incubated at 20°C
due to the fact that PVA quickly solubilizes in water at 37°C, thereby giving a rapid drug
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release. In order to overcome the problem of PVA dissolution in water, the fibers were coated
with poly(p-xylylene) so as to limit the release of proteins from the fibrous scaffolds. Incubation
of the coated mesh in water at 37°C yielded a sustained release of the drug for more than 20
days, with the protein release rate solely controlled by the water permeability of the polymer
coating. Contradictory to the fact that protein was continuously released from coated fibers for
more than 20 days at 37°C, the test for the bioactivity of the electrospun protein using
recombinant Luciferase enzyme was carried out at 4°C for only 1 day. Although the analysis
indicated that the encapsulated enzyme retained its bioactivity, it did not indicate if the fibers
succeeded as a form of protection to prolong the half-life of the protein at room temperature
or physiological conditions and also to release the encapsulated enzyme in a sustained manner.
In another study, Chew, et al., [44] electrospun a heterogeneous protein-polymer solution for
protein encapsulation. The electrospinning solution comprised of an aqueous solution of human
β-nerve growth factor (NGF), which was stabilized with bovine serum albumin (BSA) as a
carrier protein, and an organic solution of a copolymer of ε-caprolactone and ethyl ethylene
phosphate (PCLEEP) in dichloromethane. Partially aligned protein encapsulated fibers were
obtained, with the theoretical loading levels of NGF and BSA being 0.0123 and 4.08%
respectively. Incubation of the protein encapsulated fibers in serum-free RPMI medium yielded
a sustained release of NGF via diffusion for at least 3 months. The bioactivity of the electrospun
NGF was also assessed through PC12 neurite outgrowth assay, which indicated that the
bioactivity of the electrospun NGF was retained, at least partially, throughout the period of
sustained release. The study demonstrated the feasibility of encapsulating proteins via
electrospinning to produce biofunctional tissue scaffolds.
3.2.4. Glycosaminoglycan—Tri-n-butylamine salt of heparin (heparin-TBA) was loaded
at 1, 5 and 10wt % into a copolymer, poly(L-lactide-co-ε-caprolactone) (PLCL 50:50), in
attempt to immobilize and sustain release heparin from the polymeric fibrous scaffold for
vascular graft engineering applications [45]. The tri-n-butylamine salt was used instead of
heparin so that the amphiphilic salt of the glycosaminoglycan may be soluble in the polymer
solution of PLCL and 1,1,1,3,3,3-hexafluoroisopropanol. Heparin-TBA phase separated within
the PLCL nanofibers, resulting in small domains of heparin-TBA being well-dispersed
throughout the PLCL matrix, and about 2-5% of the total salt content being localized on the
surface of the fibers. In vitro release kinetics carried out in PBS at 37°C revealed an initial
∼20-30% burst release within the first 12 hours, followed by a sustained release for 4 weeks.
The release mechanism was attributed to the degradation of the copolymer due to the fact that
many fibers appeared disconnected and thin after 4 weeks of incubation, although the surface
of the fibers remained smooth. The bioactivity of the immobilized and released heparin-TBA
was, however, not evaluated, although the bioactivity of the salt was, prior to electrospinning.
3.2.5. In vivo application—The possibility of encapsulating a wide variety of drugs in
different polymers by the simple process of electrospinning suggests that electrospun drug-
encapsulated meshes may be able to find broad applicability as controlled release scaffolds,
particularly in tissue engineering applications. Zong, et al. [46] studied the use of mefoxin-
loaded electrospun fibrous meshes as scaffolds for the prevention of postsurgery induced
abdominal wound adhesion in a rat model. The drug was incorporated into electrospun PLGA
75:25 or a PEG-PLA diblock copolymer. Plain and drug-encapsulated meshes were then placed
between the defects on the abdominal wall and cecum of the rats for 28 days. The prevention
of adhesion was significantly improved with the inclusion of the electrospun fibers, presumably
due to the presence of a physical barrier provided by the fibers. It was, however, unclear whether
there was a significant difference in the prevention of adhesion between the plain and mefoxin-
loaded mesh. Nonetheless, this is the first example of an in vivo biomedical application of
electrospun fibrous mesh.
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In general, it has been demonstrated that regardless of the nature of the drug, whether low
molecular weight, protein, or plasmid DNA, the bioactivity of the drug can be retained at least
partially after electrospinning. Other than a bottom-up approach of using macromolecular self-
assembly, it is difficult to introduce biofunctionality into nanostructures. Electrospinning, with
its capability of fabricating nanofibers, represents an excellent technique of forming
biofunctional nanostructures. Coupling the biofunctionality with the simplicity and broad
applicability to a wide range of polymers, electrospinning can be expected to find many
interesting biomedical applications in the near future.
4. Electrospinning for Tissue Engineering Applications
Being an emerging field applied to tissue engineering, electrospinning has yet to make a
significant impact on in vivo applications. Although many different polymeric scaffolds and
cell types have been studied, the bulk of the research thus far is still restricted to preliminary,
qualitative analyses of the cytocompatibility of the electrospun materials in terms of cell
adhesion, proliferation and changes in cell morphology. However, increasing attention is being
paid to the more quantitative evaluation of the changes in cellular functions as a result of the
topographical cues provided by the nanofibrous scaffolds.
4.1. Cardiovascular Tissue Engineering
4.1.1. Smooth Muscle Cells—Xu, et al. [47] demonstrated the potential of poly(L-lactide-
co-ε-caprolactone) [P(LLA-CL)] (75:25) electrospun fibrous scaffolds (fiber diameter, φ, =
400-800nm) as a material for the engineering of vascular grafts. After 7 days of culture, the
human coronary artery smooth muscle cells (SMC) integrated well into the scaffold, reaching
close to 90% confluence. The SMCs also maintained their phenotypes as evidenced by being
stained positively for α-actin and myosin.
Similarly, using human coronary artery smooth muscle cells, Venugopal, et.al. [48] compared
the biocompatibility of electrospun scaffolds made of collagen type I (φ 300 – 375nm) and
poly(caprolactone) (φ 661 – 700nm) in terms of cell proliferation, cell adhesion and cell growth
rate assays after 3 days of in vitro cell culture. They concluded that while all scaffolds promoted
cell-matrix and cell-cell interactions and preserved the phenotypic morphologies of SMCs,
PCL scaffolds with collagen type I coating was the preferred choice. In such combination, the
PCL provides the desired mechanical characteristics and collagen the cytocompatibility.
With a novel approach, Stankus, et.al. [49] evaluated the feasibility of integrating high density
of vascular smooth muscle cells directly into poly(ester urethane)urea (PEUU) fibrous
scaffolds (φ not stated) during the electrospinning process, in order to obtain a well integrated,
three-dimensional distribution of cells throughout the fibrous scaffold. Two orthogonally-
positioned separate supplies of polymer and cells were used during the electrospinning process,
and despite exposure to a large electric field, cells electrosprayed from cell culture media were
found to be more than 90% viable after the fabrication process. Cellular constructs of thickness
between 300 to 500μm were obtained and cells proliferated under 7 days of transmural
perfusion culture, as compared to static culture, where cell number remained unchanged.
Cellular morphological analyses also revealed healthier-looking cells uniformly located
throughout the scaffold under perfusion culture as opposed to static culture. Comparing cells
integrated into 100μm thick constructs to cells seeded on TCPS for 7 days under static culture
conditions, integrated cells appeared to have a larger increase in cell number. Although some
extent of cellular orientation may be achieved via PEUU fiber alignment during the fabrication
process, the integration of cells, however, decreased the mechanical strength of PEUU
scaffolds.
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With the use of electrospun PLA fibrous meshes (φ ∼10μm) and collagen type I fibers
(φ=100-250μm), Stitzel, et. al. [50] fabricated a prototypic vascular graft. The authors
demonstrated that the vascular graft prototype was able to support the growth of human aortic
SMCs, with confluent layers of SMCs being observed in the luminal and external surfaces of
the vascular graft after 10 days of culture. The SMCs were also observed to align and organize
in the presence of collagen I fibers, as opposed to cells that were seeded on grafts without
collagen I fibers. The authors attributed the cell alignment to the stress exerted by the collagen
fibers, which may mimic the stress of a closed section of an artery, thereby aligning the cells.
The work was further expanded with the fabrication of a prototypic vascular graft composed
of a mixture of collagen type I, elastin and poly(D,L-lactide-co-glycolide) (PLGA) electrospun
nanofibrous scaffold (φ 0.720 ± 0.35μm) [51], in attempt to more closely mimic the mechanical
properties and material composition of a blood vessel. Bovine SMCs were used to assess the
in vitro biocompatibility of the material by seeding the cells in wells along with the electrospun
scaffolds and assessing cell viability and proliferation up to 7 days, instead of directly seeding
the cells on the electrospun scaffolds. Nonetheless, cell attachment was also evaluated by co-
culturing bovine endothelial cells and SMCs on the inner and outer surfaces of the electrospun
prototypic vascular graft respectively. Confluent layers of cells were observed after 3-4 days
of culture, demonstrating the biocompatibility of the material. In vivo biocompatibility of the
scaffold was also carried out through subcutaneous implantation of the fibrous mesh. The
evaluation of other important properties of a vascular graft, such as the leakage of fluids from
the graft and graft patency still remain to be carried out.
Since these studies with SMCs have focused only on cell-substrate interactions, one may only
conclude that electrospun fibrous scaffolds may serve as a promising scaffold for the culture
of SMC. The exact benefit of using these scaffolds, particularly nanofibrous scaffolds, for
vascular tissue engineering applications as opposed to scaffolds of other structures remain to
be addressed.
4.1.2. Endothelial Cells—The potential of electrospun poly(L-lactic acid) (PLLA) fibrous
scaffolds in supporting the growth of human vascular endothelial cells (ECs) was evaluated
by Xu et al. [52]. Electrospun scaffolds comprising of fibers with diameters of 235 ± 71 nm
and 3500 ± 854 nm respectively were studied in parallel with tissue culture polystyrene (TCPS)
and PLLA solvent-cast film as controls. Immunostaining for cell adhesion protein, CD31,
revealed that ECs appeared to adhere less well onto the electrospun scaffolds, maintaining a
rounded morphology, as compared to the typical cobblestone appearance of ECs when seeded
onto flat surfaces. Cell proliferation also appeared to be better on flat surfaces, as compared to
the fibrous scaffolds. However, no significant differences in cell behavior were observed in
cells cultured on the micro- and nano-fibrous scaffolds.
In a separate study, the same group demonstrated good interaction and integration of human
coronary artery ECs with poly(L-lactide-co-ε-caprolactone) [P(LLA-CL)] (75:25) scaffolds
(φ = 400 – 800nm) [47]. The ECs reached close to 75% confluence after 7 days of culture.
Immunostaining for CD31 and CD62E in ECs demonstrated that the cells maintained their
phenotypes. The study demonstrated the potential of P(LLA-CL) fibrous scaffolds as a material
for vascular grafts. However, since the study was done in the absence of a flat surface control,
it was inconclusive as to whether the structure of the nanofibers, hence surface roughness,
affected cell attachment and proliferation as compared to a smooth surface.
Kwon et.al. [53] studied the effects of fiber diameters on the adhesion, proliferation and
morphology of human umbilical vein endothelial cells (HUVECs). Electrospun micro- and
nano-fibrous scaffolds of a copolymer of L-lactide and ε-caprolactone, PLA-CL 50/50, were
obtained by varying the processing parameters. The authors observed that cell adhesion and
proliferation were better on the small-diameter fiber meshes (0.3 and 1.2μm diameter fibers).
Chew et al. Page 11
Curr Pharm Des. Author manuscript; available in PMC 2008 May 25.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
The cells also spread and elongated along the small-diameter meshes. In contrast, cells seeded
on the 7μm diameter fibrous mesh showed reduced cell adhesion, restricted cell spreading and
no signs of proliferation. Together with the observations made by Xu et al.[52], it appears that
a threshold fiber diameter may exist between 3.5 to 7μm to significantly affect the adhesion
and morphology of the cultured ECs.
Still using a similar polymer, He, et.al. [54] fabricated nanofibrous scaffolds (φ = 470 ± 130nm)
from a random copolymer of poly(L-lactic acid)-co-poly(ε-caprolactone), P(LLA-CL 70:30).
In order to enhance biocompatibility of the scaffold, collagen type I was used as the surface
coating, after air plasma treatment of the scaffolds. Preliminary studies to evaluate the
feasibility of the fibrous mesh as a tissue scaffold were carried out by analyzing the
morphology, viability and adhesion of human coronary artery endothelial cells on the fibrous
mesh. Cells cultured on plain P(LLA-CL) mesh adopted a rounded morphology, had a lower
viability after 3 days of culture and adhered less well to the scaffold as compared to the
collagen-coated mesh. ECs seeded on the collagen-coated mesh, however, had similar
morphology and extent of cellular attachment as compared to TCPS, indicating the importance
of protein adsorption onto the scaffold. Immunostaining for CD31 demonstrated the
preservation of EC phenotype on collagen-coated scaffolds and TCPS, but similar analysis was
not carried out on the plain P(LLA-CL) scaffolds. The similarity in cellular morphology,
attachment, preservation of phenotype, and the lower level of cell viability when cultured on
collagen-coated meshes as compared to TCPS, however, appeared to argue against the need
of the use of nanofibrous scaffolds for EC culture. Also, similar to the work by Xu, et.al [47],
the absence of a flat P(LLA-CL) surface as a control renders conclusions difficult regarding
the uniqueness or advantage of a nanofibrous scaffold as compared to a flat surface.
A similar approach was taken by Kwon and Matsuda [45] to combine the copolymer poly(L-
lactide-co-ε-caprolactone) (PLCL 50:50) with collagen type I. However, instead of serving as
a coating, collagen was blended into PLCL and electrospun into a composite fibrous mesh
(φ = 120-520nm). The advantage is perhaps the ease of introducing collagen in the single-step
process of electrospinning, as opposed to the multiple step approach taken by He, et.al [54].
HUVECs were used to evaluate the potential of the composite mesh as a tissue scaffold by
observing the cell adhesion and proliferation for up to 5 days of culture on the mesh. PLCL
scaffolds coated with fibronectin and blended with small amounts of collagen (5 and 10wt%)
were found to increase cell attachment, spreading and proliferation as compared to plain PLCL
meshes. Scaffold shrinkage due to large amounts of collagen present (30 and 50wt%) appeared
to offset the advantages of blending collagen by resulting in a much lower number of cells on
the scaffolds after 5 days of culture.
Along the same line of developing electrospun fibrous scaffolds into vascular grafts, human
coronary artery endothelial cells were cultured on electrospun poly(ethylene terephthalate)
(PET or Dacron) nanofibrous scaffolds (φ = 200-600nm) [55]. Since PET is frequently used
as replacements for large-diameter arteries, the authors wanted to evaluate the feasibility of
using PET electrospun fibrous scaffolds for EC culture as small diameter vascular grafts. ECs
cultured on TCPS, PET nanofibers and PET nanofibers with grafted gelatin were compared in
terms of cell attachment, proliferation and morphology. The authors found that gelatin grafting
onto PET fibers was necessary to achieve cell attachment. However, cell proliferation and
viability on PET, whether coated or uncoated were lower than that on TCPS. Immunostaining
showed that the expression of various adhesion molecules, namely CD31, CD106 and CD54
remained in the cells when cultured on the electrospun scaffolds, suggesting the preservation
of the EC phenotypes. The analysis, however, also indicated a decrease in expression of CD31
in cells cultured on electrospun scaffolds as compared to cells on TCPS. Although the authors
demonstrated that PET fibrous scaffolds can support EC growth to a certain extent, the scaffolds
appear to be not as ideal for EC phenotype expression as compared to TCPS. Similar to the
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results obtained by Xu et al.[52], ECs appeared to prefer smooth surfaces such as TCPS rather
than the rough surfaces provided by the PET nanofibrous scaffolds. Since a comparative study
on smooth PET films has yet to be performed, the influence of surface chemistry on cell
adhesion and proliferation cannot be eliminated.
In order to evaluate the biocompatibility of their vascular graft phenotype, which comprised
of a mixture of collagen type I, elastin and poly(D,L-lactide-co-glycolide) nanofibers (φ = 0.720
± 0.35 μm), the viability and proliferation of bovine endothelial cells were evaluated by Stitzel,
et.al. [51], by seeding the ECs in wells along with the electrospun scaffolds. Cell attachment
was also evaluated by co-culturing bovine smooth muscle cells with the ECs in the external
and luminal surfaces of the vascular prototype respectively. Results indicated that the material
was biocompatible and supported cell attachment for up to 7 and 4 days respectively.
With the studies on EC interaction with electrospun fibers put together, it appears that ECs
adhere and proliferate better on smooth surfaces. When cultured on textured surfaces provided
by electrospun fibers, there appears to be a threshold diameter, below which the effects on cell
adhesion, proliferation and morphology may be negligible. This threshold diameter may lie
between 3.5 to 7μm.
4.1.3. Primary Cardiomyocytes—Primary cardiomyocytes were cultured on three
different electrospun aligned fibrous scaffolds made of PLA, blend of PLA and PLGA 10:90
(25/75 wt%), or blend of PLGA 75:25 and PEG-PLA (85/15wt%) [56]. The authors observed
that the increase in hydrophilicity of the substrate with the inclusion of PEG resulted in
structurally compromised cell clumps. Attempts to increase the scaffold degradation rate, with
the inclusion of PLGA 10:90 also led to cells clustering together, losing their spatial
organization. Cell density, therefore, was the highest on PLLA fibers, followed by PLGA 10:90
and lastly PEG-PLA. Functional studies of the cells were also carried out using optical mapping
of electrical activity of the cells. Cells on PLLA performed better than those on the other two
scaffolds [56], by being able to follow external pacing rates up to 6 Hz (as opposed to 2Hz or
less on the other scaffolds) with shorter action potential durations. The study suggested the
possibility of using aligned electrospun fibrous scaffolds for cardiac patch engineering.
4.2. Neural Tissue Engineering
4.2.1. Neuronal Stem Cells—Electrospun poly(L-lactic acid) (PLLA) micro and
nanofibrous scaffolds comprising of either aligned or random fibers have been investigated as
a scaffold for the culture of neonatal mouse cerebellum C17.2 stem cells (NSC) [57]. The study
evaluated the effects of fiber alignment and fiber diameter on the morphology and proliferation
of the neuronal stem cells. The samples used in the study included random nanofibrous mesh
(average φ = 700nm), aligned nanofibrous mesh (average φ = 300nm), random microfibrous
mesh (average φ = 3.5μm) and aligned microfibrous mesh (average φ = 1.5μm). The neuronal
stem cells attached well onto all fibrous scaffolds, with extensive neurite-like outgrowth. They
elongated and aligned in the direction of the aligned fibers, but adopted a random morphology
on random fibrous scaffolds, thus demonstrating the contact guidance provided by the structure
of the aligned fibers. Cells were also observed qualitatively to elongate more on nanofibers as
compared to microfibers, regardless of fiber orientation. While this study suggests the
intriguing effect of nanoscale features on NSC neurite outgrowth, electrospinning will always
produce fibers with a size dispersity in diameter and imperfect alignment. It would therefore
be challenging to compare the difference between cellular behavior on electrospun microfibers
and nanofibers in a quantitative manner. Definitive conclusion would have to await studies
performed on regular nanoscale features fabricated by other nanofabrication techniques, such
as nanolithography and nanoimprinting. If the effect of nanotopography on NSC differentiation
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can be substantiated, it would have profound implications on the design of neural tissue
engineering scaffolds.
4.3. Musculoskeletal Tissue Engineering
4.3.1. Myogenic Cells and Human Satellite Cells—DegraPol, a degradable block
polyesterurethane was electrospun into microfibrous scaffolds (average φ = 10μm) for the
potential application of muscle regeneration [58]. Myogenic cells and human satellite cell
adhesion and proliferation were separately observed after 7 days of culture, with myogenic
cells staining positively for skeletal myosin heavy chain expression but negatively in the
satellite cells. The multi-nucleation of the myogenic and satellite cells on the scaffold indicated
the possibility of using these scaffolds for skeletal muscle tissue regeneration. However, cell
proliferation on the scaffolds appeared to be inferior to that on TCPS. While the ability of these
scaffolds to support cell differentiation to skeletal muscle tissues remains unclear, these
scaffolds are reportedly cell compatible.
4.3.2. Osteoblasts—Polycaprolactone/CaCO3 composite electrospun nanofibrous
scaffolds (φ = 900 ± 450nm and φ = 760 ± 190nm) have been used to culture human osteoblasts
[59]. The composite scaffolds were cyto-compatible. Cell morphology analysis revealed an
increase in granulates formation in cells seeded on composite fibers comprising of a higher
percentage of CaCO3, suggesting that differentiation of the osteoblasts might have occurred
to yield mineralization. Cell proliferation, however, appeared to be lower on the composite
fibers with higher CaCO3 content, probably due to the fact that the cells were undergoing
differentiation [59].
Human osteoblast-like cell line (MG-63) was used to evaluate the feasibility of utilizing
chitosan-poly(ethylene oxide) composite fibers as a tissue engineering scaffold [60]. The only
analysis carried out was the observation of cell-matrix interaction under scanning electron
microscope, which revealed that osteoblasts adhered to surfaces by discrete filopodia and that
the microvilli of cells appeared to attach and grow along the electrospun fibers.
In order to understand the behavior of MC3T3-E1 mouse calvaria-derived osteoprogenitor cell
line on different substratum topographies, TCPS, spin-coated PDLLA and PEG-PDLLA were
used in parallel with PDLLA, PLLA, PEG-PDLLA and PEG-PLLA electrospun fibers [61].
The authors found that alkaline phosphatase activity was not affected by the topography of the
scaffold, but cellular morphology was influenced. Cells seeded on electrospun fibers generally
had a smaller projected area than cells on flat surfaces, except for cells cultured on electrospun
scaffolds with fibers of an average diameter of 2.1μm, in which case they were possessed high
aspect ratio, similar to the case of contact guidance. The authors also found that the effect of
osteogenic factors was prominent. Cell proliferation was lower on fibrous scaffolds as
compared to smooth surfaces when osteogenic factors were left out of the cell media, but the
opposite was seen in the presence of osteogenic factors. Cell density was also found to increase
with increasing fiber diameter. The study demonstrated that cell proliferation and morphology
may be affected by the surface topography of a substrate but it has not clearly established the
pros and cons of using electrospun fibrous mesh as a tissue scaffold
3.3. Chondrocytes
Adult human articular chondrocytes [62] have been cultured on chicken sternae collagen type
II nanofibrous scaffolds (average φ= 496nm (min 70nm max 2.74μm)). The chondrocytes
adhered, proliferated and infiltrated the scaffold, indicating good cell biocompatibility of the
electrospun collagen type II scaffolds.
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With a similar objective to evaluate the biocompatibility of chitosan-PEO blended fibers, a
human chondrocyte-like cell line (HTB-94) was cultured on the fibrous meshes (φ∼ few
microns to ∼40nm) [60]. Analyses of cell attachment, morphology and viability revealed good
cell adhesion and interaction with the fibrous mesh and seemingly larger amount of live cells
on the mesh as compared to a solvent-cast film of similar material composition. The study
indicated the biocompatibility of the scaffold and the advantage of nanofibrous scaffolds over
flat surfaces.
Using a random non-woven mesh of PCL nanofibers (average φ = 700nm), the functionality
of the 3-dimensional structure of electrospun nanofibrous scaffolds in controlling
chondrogenic differentiation in fetal bovine chondrocytes (FBCs) [63] was evaluated. The de-
differentiated chondrocytes were able to re-differentiate without the addition of growth factors
after 21 days of cell culture, suggesting that the electrospun fibers may be able to stimulate the
seeded cells to release the endogenous growth factors necessary for chondrocytic
differentiation. Cells seeded on the fibers proliferated in the presence of serum. However,
differentiation of the cells was encouraged in serum-free medium. This suggested that the PCL
nanofibrous scaffolds can support both cellular proliferation and differentiation. Control over
cell proliferation and differentiation may be achieved merely by the switching of cell culture
medium from serum to serum-free medium. Cartilage-associated genes in FBCs, such as
collagen type II, collagen IX, aggrecan, and COMP were all upregulated on PCL fibrous
scaffolds as compared to cells seeded on TCPS. Changes in cellular functions was also assessed
by Alcian Blue staining, revealing a higher amount of sulfated matrix production in the FBCs
[63] seeded on electrospun scaffolds.
While most of the studies on the use of electrospun fibrous scaffolds for orthopedic implant
applications revolves around the evaluation of the cyto-compatibility of the scaffolds, the study
by Li, et al. [63] illustrated the potential of electrospun fibrous scaffolds for chondrogenic
differentiation. Electrospun scaffolds, as shown by Li, et al. [63] may have distinct advantages
over other 3-D scaffolds that are currently used for chondrogenic differentiation. Firstly, unlike
other scaffolds such as hydrogels, chondrocytes cultured on electrospun scaffolds may not
require the addition of growth factors for cartilage tissue development, and secondly,
nanofibrous scaffolds have superior mechanical integrity as opposed to hydrogels [63].
4.4. Stem Cell Engineering
4.4.1. Human Bone Marrow-Derived Mesenchymal Stem Cells (MSCs)—The cell
biocompatibility of electrospun fibrous scaffolds with MSCs were demonstrated using PLGA
85:15 electrospun nanofibrous scaffolds (φ = 500 to 800 nm) [64] and Bombyx mori silkworm
silk fibroin/PEO composite electrospun scaffolds (average φ = 700±50nm) [65] in two separate
studies by evaluating the attachment and proliferation of MSCs in the scaffolds.
In a separate, more in-depth study, PCL nanofibrous scaffolds (φ average = 700nm) were
utilized as a 3-D scaffold for chondrogenic differentiation of MSCs. The effectiveness of
electrospun scaffolds in enhancing chondrogenic differentiation was evaluated by comparing
with high density cell pellet culture in the presence of TGF-β1 [66]. Cell proliferation and the
level of MSC chondrogenesis in nanofibrous scaffolds were found to be comparable, and in
some cases, better than that in cell pellet culture. Cells were also observed to adopt a cartilage-
like morphology in the fibrous scaffolds. While collagen type II expression level was similar
in both cell pellet culture and fibrous scaffolds, collagen type IX expression was upregulated
on nanofibrous scaffolds. A continuous synthesis of sulfated glycosaminoglycans was also
observed throughout the entire duration of cell culture. These results demonstrated the
effectiveness of electrospun fibrous scaffolds in supporting chondrogenesis of MSCs, probably
due to the microstructural resemblance of the fibrous scaffolds to native collagen fibrillar
matrix [66].
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In a separate study using the same PCL nanofibrous scaffolds, the same group continued to
evaluate the potential of electrospun fibrous meshes in supporting and maintaining the
multilineage differentiation of MSCs. In showing that MSCs were able to differentiate along
adipogenic, chondrogenic and osteogenic lineages in specific differentiation media [67], the
authors concluded that indeed the conducive 3-D structure of electrospun nanofibrous scaffold
was versatile enough to support such multilineage differentiation.
4.4.2. Bone Marrow Stromal Cells (BMSCs)—Cell biocompatibility of gelatin/PCL
composite fibrous meshes (φ∼ 1 μm) were evaluated by seeding rabbit bone marrow stromal
cells (BMSCs) onto the scaffold for 7 days [68]. BMSCs were observed to stretch and spread
on the composite scaffolds instead of retaining a rounded morphology, as seen on plain PCL
scaffolds. Cells were also observed to penetrate a greater depth (114μm) into the composite
scaffold, as opposed to only 48μm from the surface of plain PCL scaffolds. The study
demonstrated the enhanced mechanical properties of the hybrid scaffold over natural polymeric
scaffolds and its improved biocompatibility over synthetic polymeric scaffolds.
The studies highlighted above underline the potential of electrospun nanofibrous scaffolds for
stem cell engineering. Electrospun fibrous scaffolds, besides providing structural support to
the cultured stem cells, may also provide the topographical signals to influence cell
differentiation, particularly through the nanostructural architecture provided by the fibers.
4.5. General Evaluation of Cytocompatibility of Electrospun Fibrous Scaffolds
Various other cell types have also been cultured on electrospun fibrous scaffolds with the aim
to evaluate the cell biocompatibility of the scaffolds. Li, et al. [64] cultured BALB/c C7 mouse
fibroblast cells on PLGA 85:15 nanofibrous scaffolds (φ = 500 to 800 nm). Min, et al. [69,
70] cultured primary normal human gingival fibroblasts, oral keratinocytes, and epidermal
keratinocytes on nanofibrous silk fibroin scaffolds (average φ = 80nm). Lastly, Khil, et al.
[71] cultured MCF – 7 mammary carcinoma cells on woven PCL fabrics (φ = 0.5 to 12 μm)
formed from a combination of electrospinning and wet spinning. Through the examination of
cell attachment, proliferation and morphology, the authors in general concluded that
electrospun fibrous scaffolds were cyto-compatible.
Although the motivation behind using nanofibrous scaffolds is to utilize the high surface-area-
to-volume ratio of the fibers to enhance cell attachment, and also to mimic the ECM in order
to control cellular functions and tissue regeneration, the majority of the research has been
limited to analyzing only cellular attachment to the scaffold, sometimes producing
contradicting results depending on the cell type and materials used. The exact benefits behind
using nanofibrous scaffolds remain to be evaluated using more in-depth assessment of cellular
functions. Nonetheless, studies available so far do illustrate the potential of electrospun fibrous
meshes in tissue engineering applications.
5. Summary
Continuous nanofibers represent a novel class of nanomaterials with interesting potential for
nanomedicine. Produced by a versatile and inexpensive electrospinning process, nanofibers
offer a unique route to combine topographical, biochemical, and mechanical (compliance) cues
to improve cell culture. The random or oriented nanofibrous structure may lead to revolutionary
biomimetic coatings and scaffolds for tissue engineering. Advances in this field would require
broad interdisciplinary effort. The fertile areas of investigation would include better theoretical
understanding of the electrospinning process, improved process control, novel characterization
approach to investigate the cell-nanofiber interactions, biofunctionalization with ligand
immobilization or drug encapsulation, and judicious application for regenerative medicine.
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Fig. 1.
Schematic of electrospinning process.
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Fig. 2.
Examples of biocompatible PEO (a), biodegradable PLGA (b), and natural collagen (c)
nanofibers produced by electrospinning.
Chew et al. Page 24
Curr Pharm Des. Author manuscript; available in PMC 2008 May 25.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 3.
Example of beaded nanofibers as a result of varicose jet instability.
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Fig. 4.
Electrospun collagen ribbons.
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Fig. 5.
Porous biodegradable PLA fiber produced by electrospinning of solution in volatile solvent
(dichloromethane).
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Fig. 6.
Schematic of conventional rotating drum for nanofiber collection and example of resulting
partially aligned nanofiber sheet.
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Fig. 7.
(a) Schematic of split electrode (gap) method of alignment and examples of unidirectional (b)
and orthogonal (c) PEO nanofiber constructs produced by this method.
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op
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ol
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T:
 p
ol
y(
et
hy
le
ne
te
re
ph
th
al
at
e)
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); 
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